ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
H2 길항제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 복합 연간 성장률(CAGR) 6.6%로 성장할 전망이며, 236억 3,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 비용 효과적인 산 감소제에 대한 수요 증가, 현대인의 라이프 스타일과 관련된 위장 장애 증가, 세계 노령화, 병용 요법의 지속적인 연구, 동물 의료에서의 용도 확대, 건강과 웰빙에 대한 소비자의 의식 증가 등에 기인한다고 생각됩니다. 예측 기간 동안 예상되는 주요 동향으로는 약물 전달 시스템의 혁신, 의약품 개발에서 인공지능(AI)의 통합, 표적 약물 전달을 위한 나노기술의 용도, 첨단 제제에 의한 생체이용률 향상, 환자 추적을 위한 디지털 건강 플랫폼 이용, 맞춤형 의료 전략 채택 등이 있습니다.
위장 질환의 유병률 증가는 향후 수년간 H2 길항제 시장의 성장을 가속할 것으로 예측됩니다. 위장(GI) 질환은 식도, 위, 장, 간, 췌장, 담낭과 같은 소화 기관에 영향을 미치는 병리입니다. 위산의 과잉 분비 및 소화기계의 염증으로 이어지는 식생활의 혼란이 주된 원인이 되고 있습니다. H2 길항제는 위산의 분비를 줄이고 위산 역류 및 궤양과 같은 질병의 치료에 효과적이므로 이러한 질병을 관리하는 데 도움이 됩니다. 신속한 증상 완화와 장기적인 소화 시스템의 건강 지원을 통해 환자의 행복을 향상시킵니다. 예를 들어 2024년 3월 스위스에 본부를 둔 유엔 전문기관인 세계보건기구(WHO)는 설사성 질환은 매년 약 17억 명의 환자를 유발하고, 5세 미만 어린이 약 44만 3,832명의 사망에 더해 5세부터 9세의 어린이 5만 8,851명의 사망 원인이 되고 있습니다. 이와 같이 위장질환의 이환율 증가는 H2 길항제 시장 확대에 박차를 가하고 있습니다.
헬스케어 지출 증가는 향후 수년간 H2 길항제 시장의 성장을 가속할 것으로 예측됩니다. 헬스케어 지출에는 의료 서비스, 치료, 인프라스트럭처, 연구, 건강 성과 향상 및 유지를 목적으로 한 공중 보건 프로그램에 대한 재정 지출 총액이 포함됩니다. 헬스케어 지출의 증가는 주로 지속적인 치료와 관리를 필요로 하는 만성질환의 만연으로 인해 장기적인 의료비가 증대됩니다. 이러한 지출의 증가는 선진적인 치료법이나 의약품에 대한 접근을 촉진함으로써 H2 길항제 시장을 지탱하고 있습니다. 또, 연구 개발 노력도 촉진되어 제제의 개선이나 환자 케어의 향상으로 이어집니다. 예를 들면, 2024년 12월, 미국의 연방 정부 기관인 메디케어 메디케이드 서비스 센터(CMS)는, 2023년의 국민 의료비(NHE)가 7.5% 증가한 4조 9,000억 달러에 이르렀으며, 국내 총생산(GDP)의 17.6%를 차지했다고 보고했습니다. 게다가 2023-2032년 NHE는 연평균 5.6%로 성장할 전망이며, GDP에서 차지하는 헬스케어 비중은 2022년 17.3%에서 2032년에는 19.7%로 증가할 것으로 예측되고 있습니다. 따라서 헬스케어 지출 증가가 H2 길항제 시장 확대에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 H2 길항제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 H2 길항제 시장 : 성장률 분석
세계의 H2 길항제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 H2 길항제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 H2 길항제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 H2 길항제 시장 : 약제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
처방전 H2 길항제
시판약 H2 길항제
세계의 H2 길항제 시장 : 적응증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
위식도 역류증(GERD)
소화성 궤양
졸린저 엘리슨 증후군
기타 적응증
세계의 H2 길항제 시장 : 제형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
태블릿
캡슐
주사액
액체 제형
세계의 H2 길항제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
소매 약국
병원 약국
온라인 약국
약국
세계의 H2 길항제 시장 : 처방 H2 길항제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
위식도 역류증(GERD)
소화성 궤양
졸린저 엘리슨 증후군
세계의 H2 길항제 시장 : 시판 H2 길항제(OTC) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
속쓰림
때때로 위산 역류 발생
소화 불량
제7장 지역별 및 국가별 분석
세계의 H2 길항제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 H2 길항제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
H2 길항제 시장 : 경쟁 구도
H2 길항제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis International AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
GlaxoSmithKline plc
Eli Lilly and Company
Teva Pharmaceutical Industries Limited
Boehringer Ingelheim International GmbH
Sun Pharmaceutical Industries Limited
Apotex Inc.
Dr. Reddy's Laboratories Limited
Apex Biotechnology Corporation
Ajanta Pharma Limited
Medochemie Ltd.
Torrent Pharmaceuticals Limited
Phathom Pharmaceuticals Inc.
Tocris Bioscience
Cadila Healthcare Limited
Modi Lifecare Industries Limited
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
H2 길항제 시장(2029년) : 새로운 기회를 제공하는 국가
H2 길항제 시장(2029년) : 새로운 기회를 제공하는 부문
H2 길항제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
H2 antagonists are a class of medications that block H2 receptors located in the lining of the stomach. By inhibiting these receptors, they reduce the production of stomach acid, which aids in healing and alleviates symptoms associated with excessive acid. These medications are widely used for treating ulcers and are available in both prescription and over-the-counter formats, making them easily accessible to patients.
The primary types of H2 antagonists include prescription and over-the-counter variants. Prescription H2 antagonists are medications that require a doctor's prescription and function to decrease the amount of acid the stomach produces. They are prescribed for several conditions, such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and others. These drugs come in various dosage forms, including tablets, capsules, liquid solutions, and injectable formulations, and are distributed through retail pharmacies, hospital pharmacies, online platforms, and drugstores.
The H2 antagonists market research report is one of a series of new reports from The Business Research Company that provides H2 antagonists market statistics, including H2 antagonists industry global market size, regional shares, competitors with an H2 antagonists market share, H2 antagonists market segments, market trends and opportunities, and any further data you may need to thrive in the H2 antagonists industry. This H2 antagonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The H2 antagonists market size has grown strongly in recent years. It will grow from $17.14 billion in 2024 to $18.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of acid-related disorders, an expanding geriatric population, heightened awareness of gastrointestinal health, cost-effectiveness compared to proton pump inhibitors, a growing number of stress-induced ulcers, and increased demand for non-invasive treatment alternatives
The H2 antagonists market size is expected to see strong growth in the next few years. It will grow to $23.63 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to the increasing demand for cost-effective acid-reducing medications, a rise in gastrointestinal disorders linked to modern lifestyles, a globally aging population, continued research into combination therapies, expanding applications in veterinary medicine, and growing consumer awareness of health and wellness. Key trends expected during the forecast period include innovations in drug delivery systems, the integration of artificial intelligence (AI) in drug development, the application of nanotechnology for targeted drug delivery, improved bioavailability through advanced formulations, the use of digital health platforms for patient tracking, and the adoption of personalized medicine strategies.
The rising prevalence of gastrointestinal disorders is anticipated to drive the growth of the H2 antagonists market in the coming years. Gastrointestinal (GI) disorders are medical conditions that affect the digestive organs, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. This growing prevalence is largely attributed to poor dietary habits, which can lead to excessive stomach acid production and irritation of the digestive system. H2 antagonists aid in managing these conditions by decreasing the production of stomach acid, making them effective in treating ailments such as acid reflux and ulcers. They improve patient well-being by providing rapid symptom relief and supporting long-term digestive health. For example, in March 2024, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that diarrheal diseases cause around 1.7 billion cases each year and are responsible for approximately 443,832 deaths among children under the age of five, in addition to 50,851 deaths among children aged five to nine. Thus, the growing incidence of gastrointestinal disorders is fueling the expansion of the H2 antagonists market.
The rising healthcare expenditure is expected to fuel the growth of the H2 antagonists market in the coming years. Healthcare expenditure encompasses the total financial outlay on medical services, treatments, infrastructure, research, and public health programs aimed at enhancing or maintaining health outcomes. The increase in healthcare spending is primarily driven by the growing prevalence of chronic diseases, which require continuous treatment and management, thereby escalating long-term medical costs. This heightened expenditure supports the H2 antagonists market by facilitating greater access to advanced therapies and medications. It also promotes research and development efforts, resulting in improved drug formulations and enhanced patient care. For instance, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a U.S.-based federal agency, reported that national health expenditures (NHE) rose by 7.5% to reach $4.9 trillion in 2023, representing 17.6% of the gross domestic product (GDP). Furthermore, between 2023 and 2032, NHE is projected to grow at an average annual rate of 5.6%, increasing the healthcare share of GDP from 17.3% in 2022 to 19.7% in 2032. Therefore, the rise in healthcare expenditure is contributing to the expansion of the H2 antagonists market.
Leading companies in the H2 antagonists market are concentrating on developing therapeutic strategies, such as generic formulations, to boost treatment effectiveness, enhance patient adherence, and prolong product lifecycles. A generic formulation is a pharmaceutical product that matches a brand-name drug in terms of dosage, strength, and method of administration. For example, in August 2022, Amneal Pharmaceuticals Inc., a U.S.-based pharmaceutical company, received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for famotidine oral suspension (40 mg/5 mL), a liquid oral H2 antagonist used for treating ulcers and gastroesophageal reflux disease (GERD). It is marketed under the reference brand Pepcid and provides a cost-effective solution for patients needing acid suppression therapy, serving as a valuable alternative in the treatment of acid reflux and ulcer-related conditions.
Major players in the h2 antagonists market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Apotex Inc., Dr. Reddy's Laboratories Limited, Apex Biotechnology Corporation, Ajanta Pharma Limited, Medochemie Ltd., Torrent Pharmaceuticals Limited, Phathom Pharmaceuticals Inc., Tocris Bioscience, Cadila Healthcare Limited, and Modi Lifecare Industries Limited.
North America was the largest region in the H2 receptor antagonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in H2 antagonists report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the H2 antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The H2 antagonists market consists of sales of ranitidine, famotidine, cimetidine, and nizatidine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
H2 Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on h2 antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for h2 antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h2 antagonists market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Prescription H2 Antagonists; Over-The-Counter H2 Antagonists
2) By Indication: Gastroesophageal Reflux Disease (GERD); Peptic Ulcer Disease; Zollinger-Ellison Syndrome; Other Indications
3) By Dosage Form: Tablets; Capsules; Injectable Solutions; Liquid Formulations
4) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies; Drug Stores
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. H2 Antagonists Market Characteristics
3. H2 Antagonists Market Trends And Strategies
4. H2 Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global H2 Antagonists Growth Analysis And Strategic Analysis Framework
5.1. Global H2 Antagonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global H2 Antagonists Market Growth Rate Analysis
5.4. Global H2 Antagonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global H2 Antagonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global H2 Antagonists Total Addressable Market (TAM)
6. H2 Antagonists Market Segmentation
6.1. Global H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prescription H2 Antagonists
Over-The-Counter H2 Antagonists
6.2. Global H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastroesophageal Reflux Disease (GERD)
Peptic Ulcer Disease
Zollinger-Ellison Syndrome
Other Indications
6.3. Global H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
Injectable Solutions
Liquid Formulations
6.4. Global H2 Antagonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Drug Stores
6.5. Global H2 Antagonists Market, Sub-Segmentation Of Prescription H2 Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastroesophageal Reflux Disease (GERD)
Peptic Ulcers
Zollinger-Ellison Syndrome
6.6. Global H2 Antagonists Market, Sub-Segmentation Of Over-The-Counter (OTC) H2 Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Heartburn
Occasional Acid Reflux
Indigestion
7. H2 Antagonists Market Regional And Country Analysis
7.1. Global H2 Antagonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global H2 Antagonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific H2 Antagonists Market
8.1. Asia-Pacific H2 Antagonists Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China H2 Antagonists Market
9.1. China H2 Antagonists Market Overview
9.2. China H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India H2 Antagonists Market
10.1. India H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan H2 Antagonists Market
11.1. Japan H2 Antagonists Market Overview
11.2. Japan H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia H2 Antagonists Market
12.1. Australia H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia H2 Antagonists Market
13.1. Indonesia H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea H2 Antagonists Market
14.1. South Korea H2 Antagonists Market Overview
14.2. South Korea H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe H2 Antagonists Market
15.1. Western Europe H2 Antagonists Market Overview
15.2. Western Europe H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK H2 Antagonists Market
16.1. UK H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany H2 Antagonists Market
17.1. Germany H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France H2 Antagonists Market
18.1. France H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy H2 Antagonists Market
19.1. Italy H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain H2 Antagonists Market
20.1. Spain H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe H2 Antagonists Market
21.1. Eastern Europe H2 Antagonists Market Overview
21.2. Eastern Europe H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia H2 Antagonists Market
22.1. Russia H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America H2 Antagonists Market
23.1. North America H2 Antagonists Market Overview
23.2. North America H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA H2 Antagonists Market
24.1. USA H2 Antagonists Market Overview
24.2. USA H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada H2 Antagonists Market
25.1. Canada H2 Antagonists Market Overview
25.2. Canada H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America H2 Antagonists Market
26.1. South America H2 Antagonists Market Overview
26.2. South America H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil H2 Antagonists Market
27.1. Brazil H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East H2 Antagonists Market
28.1. Middle East H2 Antagonists Market Overview
28.2. Middle East H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa H2 Antagonists Market
29.1. Africa H2 Antagonists Market Overview
29.2. Africa H2 Antagonists Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa H2 Antagonists Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa H2 Antagonists Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. H2 Antagonists Market Competitive Landscape And Company Profiles
30.1. H2 Antagonists Market Competitive Landscape
30.2. H2 Antagonists Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
31. H2 Antagonists Market Other Major And Innovative Companies
31.1. GlaxoSmithKline plc
31.2. Eli Lilly and Company
31.3. Teva Pharmaceutical Industries Limited
31.4. Boehringer Ingelheim International GmbH
31.5. Sun Pharmaceutical Industries Limited
31.6. Apotex Inc.
31.7. Dr. Reddy's Laboratories Limited
31.8. Apex Biotechnology Corporation
31.9. Ajanta Pharma Limited
31.10. Medochemie Ltd.
31.11. Torrent Pharmaceuticals Limited
31.12. Phathom Pharmaceuticals Inc.
31.13. Tocris Bioscience
31.14. Cadila Healthcare Limited
31.15. Modi Lifecare Industries Limited
32. Global H2 Antagonists Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The H2 Antagonists Market
34. Recent Developments In The H2 Antagonists Market
35. H2 Antagonists Market High Potential Countries, Segments and Strategies
35.1 H2 Antagonists Market In 2029 - Countries Offering Most New Opportunities
35.2 H2 Antagonists Market In 2029 - Segments Offering Most New Opportunities
35.3 H2 Antagonists Market In 2029 - Growth Strategies
